Kyntra Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KYNB research report →
Range $28 – $28
Price Chart
About the company
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF).
- CEO
- Thane Wettig
- IPO
- 2014
- Employees
- 34
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on KYNB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.32M
- P/E
- 0.21
- PEG
- 0.00
- P/S
- 1.40
- P/B
- -0.25
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
- Gross Margin
- 19.59%
- Op Margin
- -1099.92%
- Net Margin
- 657.67%
- ROE
- -104.75%
- ROIC
- -538.71%
Latest fiscal year · YoY change
- Revenue
- $6.44M-78.3%
- Gross Profit
- $5.88M-58.2%
- Op Income
- $-45,895,000
- Net Income
- $183.45M+485.6%
- EPS
- $45.37+481.6%
- OCF Growth
- +96.5%
- FCF Growth
- +96.5%
- 52W High
- $10.47
- 52W Low
- $1.54
- 50D MA
- $5.36
- 200D MA
- $6.74
- Beta
- 1.10
- RSI (14)
- 13
- Avg Volume
- 30.00K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kyntra Bio exited the quarter with a cleaner balance sheet and over $44 million in cash, but it is winding down its FG-3246 program after weak interim efficacy and is now focused on funding a 2027 roxadustat phase III study.· November 16, 2026
- FG-3246/FG-3180 was terminated after a pre-planned interim analysis showed insufficient efficacy to continue development.
- The company is returning the asset to Fortis and expects to save about $20 million in operating expenses across 2027 and 2028.
- Kyntra is now a pure-play rare disease company focused on roxadustat for anemia in lower-risk MDS, especially high transfusion burden patients.
- NovaQuest royalty obligations were reduced from $125 million to $65 million, with remaining capped payments of $15 million.
- Management still targets phase III initiation in Q1 2027, but only if it secures either a strategic partnership or external capital.
Third-quarter 2026 total revenue was $1.8 million versus $1.1 million in the same period of 2025. Total operating costs and expenses were $14.6 million versus $6.5 million a year ago, with R&D at $8.3 million versus $1.2 million and SG&A at $5.8 million versus $5.3 million. Net income from continuing operations was $0.2 million, or $0.04 per basic and diluted share, compared with a net loss of $13.1 million, or $3.25 per basic and diluted share, last year, driven by a $14 million gain on debt restructuring. As of September 30, 2026, cash equivalents, investments, and accounts receivable were $44.1 million. For roxadustat, management said it remains on track to start phase III in Q1 2027, subject to a strategic partnership or external capital raise; interim analysis is expected in the second half of 2028 and primary analysis in the first half of 2030. They also said the company expects cash runway into 2028.
Thane Wettig framed the quarter as a strategic pivot away from an unsuccessful oncology asset and toward a more focused rare-disease story. He emphasized that the roxadustat program is built on post-hoc MATTERHORN data, FDA feedback, and what he described as a substantial unmet need in lower-risk MDS, especially for patients with high transfusion burden. His tone was candid about the FG-3246 outcome but constructive and confident about roxadustat, repeatedly stressing operational readiness and the need to secure funding before launch.
David DeLucia highlighted the NovaQuest amendment as a major balance-sheet improvement: the maximum aggregate payment obligation fell from $125 million to $65 million, after a $42.6 million upfront payment in Q3 that brought total payments to $50 million. Remaining payments are capped at $15 million and funded from 50% of Astellas revenue in covered territories excluding Japan. On the quarter, he reported $1.8 million in revenue, $14.6 million in operating costs and expenses, and a cash position of $44.1 million. He said the FG-3246 wind-down should reduce operating expenses by over $20 million across 2027 and 2028 and that cash runway now extends into 2028.
Analysts focused heavily on two issues: whether Kyntra would disclose more data on FG-3246, and whether the small roxadustat data set would make partnering or financing difficult. Management said FG-3246 results will be disclosed in some form, but there was no support for continuing development and no CD46 expression analysis had yet been completed. On roxadustat, management argued the existing data are sufficient to move into phase III, saying another phase II study would cost time and money without materially changing the case, and that partners have shown interest. Questions also covered enrollment, the futility interim, and safety; management said the interim will be strictly for futility, enrollment is modeled at 201 patients over 24 months across 100-110 sites, and the FDA accepted the proposed dose and titration approach while allowing tighter eligibility criteria to manage thrombotic/cardiovascular risk.
The company now has a clearer strategic identity and a stronger cash profile after reducing NovaQuest obligations and adding more than $20 million of expected expense savings. Management believes roxadustat has encouraging efficacy signals in the high transfusion burden subgroup, including responses across RS-negative and RS-positive patients, and sees an oral, potentially differentiated option in a setting with meaningful unmet need. They also said the FDA did not object to the proposed dosing strategy for the phase III study.
The immediate negative is that FG-3246 was terminated for insufficient efficacy, eliminating that program and forcing a wind-down of associated work. Roxadustat still needs financing or a partnership before phase III can start, and the evidence base is based on post-hoc analyses rather than a dedicated pivotal readout. Management also acknowledged thrombotic and Grade 3 adverse events in the roxadustat data, even if they believe the risk is manageable and consistent with the broader MDS treatment setting.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.1%
- Shares Outstanding
- 4.05M
- Float Shares
- 3.57M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 22 ETFs
Biggest fund positions in KYNB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 26 | Wettig Thane | other | 2,500 |
| Oct 1, 26 | Singer Andrew E. | other | 14,000 |
| Oct 1, 26 | Singer Andrew E. | other | 0 |
| Sep 6, 26 | Wettig Thane | other | 209 |
| Sep 6, 26 | DeLucia David | other | 22 |
| Jun 12, 26 | Ho Maykin | other | 7,000 |
| Jun 12, 26 | EDWARDS JEFFREY L | other | 7,000 |
| Jun 12, 26 | Kauffman Michael | other | 7,000 |
| Jun 12, 26 | Schoeneck James A | other | 7,000 |
| Jun 6, 26 | Wettig Thane | other | 198 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KYNB coverage
Recent articles, reports, and earnings notes.
No research on KYNB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KYNB report →Kyntra Bio, Inc. (KYNB) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 18
Kyntra Bio (KYNB) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 16
Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 16
Kyntra Bio to Report Third Quarter 2026 Financial Results
globenewswire.com · Nov 13
Kyntra Bio Inc (NASDAQ:KYNB) Stock Has Average Price Target of $36.80 According to Analysts
defenseworld.net · Nov 11
Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrast
defenseworld.net · Oct 9
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
globenewswire.com · Oct 1
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.